Article
Clinical utility of the ARCHITECT HCV Ag assay for early treatment monitoring in patients with chronic hepatitis C genotype 1 infection.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology - 1 Sept 2012
Vermehren Johannes, Susser Simone, Berger Annemarie, Perner Dany, Peiffer Kai-Henrik, Allwinn Regina, Zeuzem Stefan, Sarrazin Christoph
Abstract excerpt
BACKGROUND: Virologic response-monitoring is essential for determining therapy duration in patients with chronic hepatitis C virus (HCV) infection. This is usually performed using highly sensitive HCV-RNA assays. However, HCV-RNA assays are time-consuming, expensive and require highly trained personnel. Quantitative determination of HCV core-antigen (HCVAg) levels may be used to supplement treatment monitoring....
Topics
- Adult
- Aged
- Antiviral Agents
- Drug Monitoring
- Female
- Genotype
- Hepacivirus
- Hepatitis C Antigens
- Hepatitis C, Chronic
- Humans
